Lucas Silva Cortes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lucas Silva Cortes has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Claudia Saad-Magalhaes
Pediatric Rheumatology Divison, Botucatu Medical School, São Paulo State University (UNESP), Botucatu, Brazil
1 shared publication - Douglas Squizatto Leite
Rheumatology Division, Botucatu Medical School, São Paulo State University (UNESP), Botucatu, Brazil
1 shared publication - Luciana Patrícia Fernandes Abbade
Department of Infectology, Dermatology, Imaging Diagnosis and Radiotherapy, Faculty of Medicine, Universidade Estadual Paulista, Botucatu, SP, Brazil
1 shared publication - Maria Aparecida Custódio Domingues
UNESP, Brazil
1 shared publication - Simone Antunes Terra
Pathology Department, Faculdade de Medicina de Botucatu, Universidade Estadual Paulista "Júlio de Mesquita Filho", Botucatu, SP, Brazil
1 shared publication - Taciana de Albuquerque Pedrosa Fernandes
Pediatric Rheumatology Divison, Botucatu Medical School, São Paulo State University (UNESP), Botucatu, Brazil
1 shared publication
Latest Publications
- Open Access
- 23 January 2026
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 101 (1)
Necrobiose lipoídica ulcerada: apresentação clínica e histopatológica de dois casos
- 23 January 2026
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 101 (1)
Open AccessNecrobiose lipoídica ulcerada: apresentação clínica e histopatológica de dois casos
- Open Access
- 2 December 2025
- Published by Springer Nature in Advances in Rheumatology
- Vol. 66 (1)
Hyperinflammatory status associated with COVID-19: clinical features of a pediatric series
Objective: Explore clinical features, atypical manifestations and rare autoimmune complications of pediatric hyperinflammatory manifestations associated to SARS-CoV-2, observed during the COVID-19 pandemic, and the relationship of Multisystemic Inflammatory Syndrome of Childhood (MIS-C) with other manifestations, such as macrophage activation syndrome, vasculitis and vasculopathy. Methods: A protocol with detailed socio-demographic and clinical features, SARS-CoV-2 exposure and morbidity was conducted in a public tertiary hospital as part of a multicentric international protocol. Cases were selected and enrolled in a single centre from 2020 to 2022, recording all the organ and systems manifestations, standard treatment and outcome. Results: Of the 23 suspicious cases, 21 met the inclusion criteria of MIS-C. Gastrointestinal manifestations were frequent, and three out of 21 had acute abdomen, one with documented histiocytic necrotizing mesenteric lymphadenopathy (Kikuchi-Fujimoto), 3 had macrophage activation syndrome (MAS), and one case, with previous enthesitis related arthritis evolved into type V Takayasu arteritis and malignant hypertension. All patients were treated with either intravenous immunoglobulin (IVIG), high dose glucocorticoids or both, five were under intensive care treatment with respiratory and cardio-circulatory support. All had full recovery during acute phase. Description the lymphonode histopathology showed proliferation of small lymphocytes and macrophage infiltrates with microthrombi and lymph nodes germinal centers necrosis. Conclusion: Post-infectious hyperinflammatory states associated with COVID-19 manifestations may cause not only to transient inflammatory features, but also autoimmunity, vasculitis and vasculopathy manifestations that require prompt treatment.
- 2 December 2025
- Published by Springer Nature in Advances in Rheumatology
- Vol. 66 (1)
Open AccessHyperinflammatory status associated with COVID-19: clinical features of a pediatric series
Objective: Explore clinical features, atypical manifestations and rare autoimmune complications of pediatric hyperinflammatory manifestations associated to SARS-CoV-2, observed during the COVID-19 pandemic, and the relationship of Multisystemic Inflammatory Syndrome of Childhood (MIS-C) with other manifestations, such as macrophage activation syndrome, vasculitis and vasculopathy. Methods: A protocol with detailed socio-demographic and clinical features, SARS-CoV-2 exposure and morbidity was conducted in a public tertiary hospital as part of a multicentric international protocol. Cases were selected and enrolled in a single centre from 2020 to 2022, recording all the organ and systems manifestations, standard treatment and outcome. Results: Of the 23 suspicious cases, 21 met the inclusion criteria of MIS-C. Gastrointestinal manifestations were frequent, and three out of 21 had acute abdomen, one with documented histiocytic necrotizing mesenteric lymphadenopathy (Kikuchi-Fujimoto), 3 had macrophage activation syndrome (MAS), and one case, with previous enthesitis related arthritis evolved into type V Takayasu arteritis and malignant hypertension. All patients were treated with either intravenous immunoglobulin (IVIG), high dose glucocorticoids or both, five were under intensive care treatment with respiratory and cardio-circulatory support. All had full recovery during acute phase. Description the lymphonode histopathology showed proliferation of small lymphocytes and macrophage infiltrates with microthrombi and lymph nodes germinal centers necrosis. Conclusion: Post-infectious hyperinflammatory states associated with COVID-19 manifestations may cause not only to transient inflammatory features, but also autoimmunity, vasculitis and vasculopathy manifestations that require prompt treatment.